New York, May 26, 2026, 13:08 EDT
- Standard BioTools traded up 4.4% at $1.075 during early afternoon, with volume around 1.19 million shares.
- LAB is holding above Nasdaq’s $1 minimum bid, but the company hasn’t hit the closing-price streak it needs yet to be back in compliance.
- Standard BioTools Inc. reported first-quarter results with some revenue growth and lower costs, but instrument demand stayed weak.
Standard BioTools Inc. shares moved back over $1 on Tuesday, as the life-science tools company’s Nasdaq listing status was again in play coming off the U.S. holiday weekend.
The stock rose 4.4% to $1.075 early in the afternoon, hitting its session high. It started the day at $1.03 and touched a low of $1.025. Market cap stood near $417 million.
Standard BioTools needs to stay above $1 now. Nasdaq warned the company in April that its stock dipped below the exchange’s $1 minimum bid price rule, which means the closing bid has to stay at or above $1.
Trading continues as usual for now. Standard BioTools has until Oct. 19, 2026, to fix the issue. The company needs its shares to close at $1 or higher for 10 straight business days to comply.
Small-cap and biotech stocks caught a bid Tuesday. The iShares Russell 2000 ETF added roughly 1.5%, and the SPDR S&P Biotech ETF rose about 1.0%. Among life-science tools names, 10x Genomics jumped 4.6%. Bruker gained 2.8%. Bio-Techne was flat.
No new earnings have come out linked to the move. The most recent numbers are still from the May 5 Q1 report, which posted revenue of $21.1 million, a 5% rise from last year.
Investors got a mixed signal from the report. Consumables revenue climbed 35% to $11.0 million, but instruments sales dropped 33% to $4.5 million as customers put off major buys. Services revenue came in up 5% at $5.7 million.
Costs came in lower. Operating expenses dropped 37% to $23.8 million. Adjusted EBITDA loss narrowed to $3.1 million, compared with a loss of $14.1 million a year ago.
Standard BioTools CEO Michael Egholm called it a “strong start to 2026” and said cost cuts were helping the company move toward profitability this year. Egholm said the company is “fully focused on strategic capital deployment” now that it has closed the sale of SomaLogic to Illumina. Standard BioTools Inc.
SomaLogic’s sale is still the key balance-sheet event. Standard BioTools wrapped the $350 million upfront deal on Jan. 30, also getting potential earnouts of up to $75 million, according to company releases. Standard BioTools posted $523.6 million in cash, restricted cash, and liquid investments at the end of the quarter, not including a $25 million earnout that arrived after the quarter closed.
But just trading over $1 isn’t enough to solve the listing issue. The company needs to close above that level for a stretch. The main business worry is still whether cash from selling SomaLogic will make a difference while instrument sales are slow. Standard BioTools also said there’s no guarantee of getting back in line with Nasdaq rules.
